Evidence map›Paper›PMID 34111811›Full record

ArticleThrombosis research2021

Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma.

Anton Ilich, Vaibhav Kumar, Michael J Ferrara, Michael W Henderson, Denis F Noubouossie, Donald H Jenkins, Rosemary A Kozar, Myung S Park, Nigel S Key

Open access · greenAbstract read
In one paragraph

Article in Thrombosis research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Anton IlichDivision of Hematology, Department of Medicine and Blood Research Center, University of North Carolina, Chapel Hill, NC, USA.
Vaibhav KumarDivision of Hematology, Department of Medicine and Blood Research Center, University of North Carolina, Chapel Hill, NC, USA.
Michael J FerraraDepartment of Surgery, Mayo Clinic, Rochester, MN, USA.
Michael W HendersonDivision of Hematology, Department of Medicine and Blood Research Center, University of North Carolina, Chapel Hill, NC, USA.
Denis F NoubouossieDivision of Hematology, Department of Medicine and Blood Research Center, University of North Carolina, Chapel Hill, NC, USA.
Donald H JenkinsDepartment of Surgery, UT San Antonio, San Antonio, TX, USA.
Rosemary A KozarR. Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Myung S ParkDepartment of Surgery, Mayo Clinic, Rochester, MN, USA.
Nigel S KeyDivision of Hematology, Department of Medicine and Blood Research Center, University of North Carolina, Chapel Hill, NC, USA. Electronic address: nigel_key@med.unc.edu.
University of North Carolina at Chapel Hill · USMayo Clinic in Arizona · USUniversity of Maryland, Baltimore · USUrology San Antonio · US

Funding

Research Training in Hematology at UNC Chapel HillT32HL007149 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nigel S. Key · 1985 to 2026
$8.6M
Predictors of Venous Thromboembolism: A Multicenter Prospective Cohort StudyR01GM126086 · NIGMS · MAYO CLINIC ROCHESTER · PI PARK, MYUNG SOO · 2018 to 2022
$3.4M
Mechanism of sickle cell disease-specific venous thromboembolismR01HL157441 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KEY, NIGEL S., PAWLINSKI, RAFAL L · 2021 to 2024
$2.6M
Fibrinolysis Evaluation in A-TREAT (‘FEAT’ Study)R01HL146226 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KEY, NIGEL S. · 2019 to 2021
$1.2M
NHLBI NIH HHS R01 HL146226NHLBI NIH HHS R01 HL157441NHLBI NIH HHS T32 HL007149NIGMS NIH HHS R01 GM126086
6 · The paper itself

Abstract

Activation of the fibrinolytic system plays a central role in the host response to trauma. There is significant heterogeneity in the degree of fibrinolysis activation at baseline that is usually assessed by whole blood thromboelastography (TEG). Few studies have focused on plasma markers of fibrinolysis that could add novel insights into the frequency and mechanisms of fibrinolytic activation in trauma. Global fibrinolysis in plasma was assessed using a modified euglobulin clot lysis time (ECLT) assay in 171 major trauma patients and compared to commonly assessed analytes of fibrinolysis. The median ECLT in trauma patients was significantly shorter at 8.5 h (IQR, 1.3-19.5) compared to 19.9 h (9.8-22.6) in healthy controls (p < 0.0001). ECLT values ≤2.5th percentile of the reference range were present in 83 (48.5%) of trauma patients, suggesting increased fibrinolytic activation. Shortened ECLT values were associated with elevated plasmin-antiplasmin (PAP) complexes and free tissue plasminogen activator (tPA) levels in plasma. Sixteen (9.2%) individuals met the primary outcome for massive transfusion, here defined as the critical administration threshold (CAT) of 3 units of packed red cells in any 60-minute period within the first 24 h. In a univariate screen, plasma biomarkers associated with CAT included D-dimer (p < 0.001), PAP (p < 0.05), free tPA (p < 0.05) and ECLT (p < 0.05). We conclude that fibrinolytic activation, measured by ECLT, is present in a high proportion of trauma patients at presentation. The shortened ECLT is partially driven by high tPA levels and is associated with high levels of circulating PAP complexes. Further studies are needed to determine whether ECLT is an independent predictor of trauma outcomes.

Indexed as

FibrinolysisTissue Plasminogen ActivatorFibrin Clot Lysis TimeHumansThrombelastographyThrombolytic TherapyTissue Plasminogen ActivatorD-dimerEuglobulin clot lysis timeFibrinolysisPlasmin-antiplasmin complexesTissue plasminogen activatorTrauma

Identifiers

PMID34111811
PMCPMC8277746
OpenAlexW3172199543

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.